Comprehensive in vitro characterization of PD-L1 small molecule inhibitors

Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction has emerged as a powerful strategy in cancer immunotherapy. Recently, there have been enormous efforts to develop potent PD-1/PD-L1 inhibitors. In particular, Bristol-Myers Squibb (BMS) and Aurigene Dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganesan, Aravindhan, Ahmed, Marawan, Okoye, Isobel, Arutyunova, Elena, Babu, Dinesh, Turnbull, William L., Kundu, Joydeb Kumar, Shields, Justin, Agopsowicz, Katharine Cheryl, Xu, Lai, Tabana, Yasser, Srivastava, Nutan, Zhang, Guangzhi, Moon, Tae Chul, Belovodskiy, Alexandr, Hena, Mostofa, Kandadai, Appan Srinivas, Hosseini, Seyedeh Nargess, Hitt, Mary, Walker, John, Smylie, Michael, West, Frederick G., Siraki, Arno G., Lemieux, M. Joanne, Elahi, Shokrollah, Nieman, James A., Tyrrell, D. Lorne, Houghton, Michael, Barakat, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712002/
https://www.ncbi.nlm.nih.gov/pubmed/31455818
http://dx.doi.org/10.1038/s41598-019-48826-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712002/
https://www.ncbi.nlm.nih.gov/pubmed/31455818
http://dx.doi.org/10.1038/s41598-019-48826-6

Ejemplares similares